US 11,987,644 B2
Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies
Michael Otto Bardroff, Loerrach (DE); Tina Buch, Efringen-Kirchen (DE); Christian Graf, Munich (DE); Daniel Heitmann, Zürich (CH); Thomas Jostock, Neuenburg am Rhein (DE); Hans-Peter Knopf, Schallstadt (DE); Rolf Koehler, Basel (CH); Jiri Kovarik, Zürich (CH); Stephen John Oliver, Basel (CH); Dhavalkumar Patel, Basel (CH); and Maximilian Woisetschlaeger, Oberwil (CH)
Assigned to NOVARTIS AG, Basel (CH)
Filed by NOVARTIS AG, Basel (CH)
Filed on Apr. 9, 2020, as Appl. No. 16/844,999.
Application 16/844,999 is a continuation of application No. 16/005,088, filed on Jun. 11, 2018, abandoned.
Claims priority of provisional application 62/518,090, filed on Jun. 12, 2017.
Prior Publication US 2020/0308309 A1, Oct. 1, 2020
Int. Cl. C07K 16/00 (2006.01); A61P 1/00 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 9/14 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/468 (2013.01) [A61P 1/00 (2018.01); A61P 9/10 (2018.01); A61P 9/14 (2018.01); C07K 16/00 (2013.01); C07K 16/244 (2013.01); C07K 16/245 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/46 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2319/00 (2013.01)] 4 Claims
 
1. A bispecific antibody, wherein the bispecific antibody binds to IL-18 and IL-1β and comprises:
a first immunoglobulin heavy chain comprising the amino acid sequence SEQ ID NO. 87;
a first immunoglobulin light chain comprising the amino acid sequence SEQ ID NO. 103;
a second immunoglobulin heavy chain comprising the amino acid sequence SEQ ID NO. 55; and
a second immunoglobulin light chain comprising the amino acid sequence SEQ ID No. 71.